NASDAQ : RNA
Atrium Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.26 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 141.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 146.42M |
| Enterprise Value | -115.79M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 17.11M |
| Shares Outstanding | 17.11M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 3.29% |
| Owned by Institutions (%) | 75.38% |
| Float | 15.04M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.04 |
| Forward PS | 11.67 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.73 |
| Quick Ratio | 8.38 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -27.80% |
| Weighted Average Cost of Capital (WACC) | 9.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -142,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.93 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 9.77 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.82 |
| Average Volume (20 Days) | 249,024 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.73M |
| Short Previous Month | 3.40M |
| Short % of Shares Out | 6.62% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 35.84M |
| Gross Profit | -20.20M |
| Operating Income | -69.21M |
| Pretax Income | -66.13M |
| Net Income | -65.99M |
| EBITDA | -68.53M |
| EBIT | -69.21M |
| Loss Per Share | -$3.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 263.90M |
| Total Debt | 1.68M |
| Net Cash | 262.22M |
| Net Cash Per Share | $15.33 |
| Equity (Book Value) | 214.58M |
| Book Value Per Share | 12.54 |
| Working Capital | 243.54M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -53.19M |
| Capital Expenditures | -3.31M |
| Depreciation & Amortization | 685,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -56.50M |
| FCF Per Share | -$3.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | -56.37% |
| Operating Margin | -193.13% |
| Pretax Margin | -184.54% |
| Profit Margin | -184.14% |
| EBITDA Margin | -191.22% |
| EBIT Margin | -193.13% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -45.07% |
| FCF Yield | -39.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $22.00 |
| Price Target Difference | 157.01% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.27 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |